Boule Diagnostics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Torben Nielsen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

CEO

Torben Nielsen

no data

Tenure

Mr. Torben Nielsen is Chief Executive Officer and Group President of Boule Diagnostics AB (publ). Mr. Nielsen joined the Boule Diagnostics AB (publ) in April 2024.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Torben Nielsen	CEO & Group President	no data	geen gegevens	geen gegevens
Holger Lembrer	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Eduardo Pagani	Chief Operating Officer	no data	geen gegevens	geen gegevens
Jorgen Jehander	Head of Development Department & Interim CTO	1.8yrs	geen gegevens	geen gegevens
Simonetta Tumbiolo	Senior Vice President of Marketing	less than a year	geen gegevens	geen gegevens
Aishat Bislieva	Senior Vice President of People & Culture	2.1yrs	geen gegevens	geen gegevens
David Metrena	Senior Vice President of Commercial Operations of US	2.4yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van 8BD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yvonne Martensson	Independent Director	3.5yrs	SEK 500.00k	0.038% € 9.5k
Thomas Eklund	Director	10.8yrs	SEK 300.00k	10.4% € 2.6m
Karin Dahllof	Independent Director	9.8yrs	SEK 250.00k	0.057% € 14.3k
Rikke Rytter	Director	less than a year	geen gegevens	geen gegevens
Emil Hjalmarsson	Director	2.8yrs	SEK 125.00k	0.067% € 16.7k
Torben Jorgensen	Independent Chairman of the Board	3.8yrs	SEK 250.00k	0.051% € 12.8k

3.7yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8BD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Boule Diagnostics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Boule Diagnostics AB (Publ) Appoints Rikke Rytter as Director

President recently bought €88k worth of stock

Boule Diagnostics AB (publ), Annual General Meeting, May 04, 2023

President recently bought €12k worth of stock

Independent Chairman of the Board recently bought €113k worth of stock

President recently bought €9.8k worth of stock

Recent updates

Third quarter 2024 earnings released: kr5.90 loss per share (vs kr0.12 profit in 3Q 2023)

New minor risk - Share price stability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.11 profit in 2Q 2023)

Boule Diagnostics AB (Publ) Appoints Rikke Rytter as Director

First quarter 2024 earnings released: EPS: kr0.25 (vs kr0.20 in 1Q 2023)

Full year 2023 earnings released: EPS: kr0.64 (vs kr0.46 in FY 2022)

Boule Diagnostics AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

New minor risk - Share price stability

Full year 2023 earnings released: EPS: kr0.64 (vs kr0.46 in FY 2022)

Boule Diagnostics AB (publ) to Report Q2, 2024 Results on Jul 22, 2024

Second quarter 2023 earnings released: EPS: kr0.11 (vs kr0.15 in 2Q 2022)

Boule Diagnostics AB (publ) to Report Q1, 2024 Results on May 07, 2024

Full year 2022 earnings released: EPS: kr0.46 (vs kr1.20 in FY 2021)

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Nov 09, 2023

Boule Diagnostics AB (publ) to Report Q3, 2023 Results on Sep 09, 2023

President recently bought €88k worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: kr0.15 (vs kr0.07 loss in 2Q 2021)

Boule Diagnostics AB (publ), Annual General Meeting, May 04, 2023

Boule Diagnostics AB (publ) to Report Q1, 2023 Results on May 03, 2023

First quarter 2022 earnings released: EPS: kr0.24 (vs kr0.02 in 1Q 2021)

Upcoming dividend of kr0.55 per share

Full year 2021 earnings released: EPS: kr1.20 (vs kr2.47 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS kr0.37 (vs kr1.04 in 3Q 2020)

President recently bought €12k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr2.21 loss in 2Q 2020)

First quarter 2021 earnings released

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Independent Chairman of the Board recently bought €113k worth of stock

Full year 2020 earnings released: kr2.47 loss per share (vs kr1.93 profit in FY 2019)

Revenue misses expectations

Boule Diagnostics AB (publ) to Report Fiscal Year 2020 Results on Feb 03, 2021

New 90-day high: €5.65

Third quarter 2020 earnings released: EPS kr1.04

Revenue misses expectations

New 90-day low: €4.82

President recently bought €9.8k worth of stock

New 90-day low: €5.09

President recently bought €16k worth of stock

Boule Diagnostics AB (publ) to Report Q1, 2021 Results on May 06, 2021

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd